The New Kid on the Block: A Retrospective Multicenter Real-World Experience with Maribavir for Cytomegalovirus Infection in Pediatric Transplant and Cellular Therapy Recipients

This multicenter retrospective case series characterizes maribavir (MBV) use for cytomegalovirus (CMV) infection in 62 immunocompromised children treated at 18 United States centers from 2015 through 2024. The most common indications for use were suspected antiviral resistance (45.2%), documented resistance (19.4%), and lack of appropriate alternative agents (11.3%). Among 59 participants with detectable CMV DNAemia when their first course began, 66.1% had complete response, 5.1% had partial response, 27.1% had no response, and one relapsed before treatment cessation. CMV DNAemia ≥50,000 IU/mL was associated with a lower response rate, and MBV resistance was identified in four participants. Across 70 total treatment episodes, 21.4% reported adverse events and discontinuation attributed to MBV occurred in 5.7%. Concomitant use of MBV and other anti-CMV directed medications occurred frequently. Although efficacy results are limited by the observational design, these results highlight real-world pediatric experience and safety.

Authors

Institutions

Publication Details

Journal
Journal of the Pediatric Infectious Diseases Society
Published
2026-11-18
DOI
https://doi.org/10.1093/jpids/piag121
Primary Topic
Cytomegalovirus and herpesvirus research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

The New Kid on the Block: A Retrospective Multicenter Real-World Experience with Maribavir for Cytomegalovirus Infection in Pediatric Transplant and Cellular Therapy Recipients

Claire Elizabeth Bocchini, Eunkyung Song, Kathryn P. Goggin, Yeh-Chung Chang et al.
4 links
Journal of the Pediatric Infectious Diseases Society
Cytomegalovirus and herpesvirus research
article

The New Kid on the Block: A Retrospective Multicenter Real-World Experience with Maribavir for Cytomegalovirus Infection in Pediatric Transplant and Cellular Therapy Recipients

Claire Elizabeth Bocchini, Eunkyung Song, Kathryn P. Goggin, Yeh-Chung Chang, Elizabeth Doby Knackstedt, Marc D. Foca, Shannon L. Andrews, Surabhi B Vora, William R Otto, Taylor A. Heald-Sargent, Joana Dimo, Jonathan D. Albert, Diego R. Hijano, Tanvi S Sharma, Gabriela Maria Marón, Benjamin R Hanisch, Mary Suzanne Whitworth, Lara A. Danziger‐Isakov, Kari Neemann, Antigone Kraft, Madeline Johnson, Kay Leopold
article en

Abstract

This multicenter retrospective case series characterizes maribavir (MBV) use for cytomegalovirus (CMV) infection in 62 immunocompromised children treated at 18 United States centers from 2015 through 2024. The most common indications for use were suspected antiviral resistance (45.2%), documented resistance (19.4%), and lack of appropriate alternative agents (11.3%). Among 59 participants with detectable CMV DNAemia when their first course began, 66.1% had complete response, 5.1% had partial response, 27.1% had no response, and one relapsed before treatment cessation. CMV DNAemia ≥50,000 IU/mL was associated with a lower response rate, and MBV resistance was identified in four participants. Across 70 total treatment episodes, 21.4% reported adverse events and discontinuation attributed to MBV occurred in 5.7%. Concomitant use of MBV and other anti-CMV directed medications occurred frequently. Although efficacy results are limited by the observational design, these results highlight real-world pediatric experience and safety.

Journal of the Pediatric Infectious Diseases Society
Cincinnati Children's Hospital Medical Center (US), Boston Children's Hospital (US), Lurie Children's Hospital (US), Seattle Children's Hospital (US), Albert Einstein College of Medicine (US), University of Minnesota (US), St. Jude Children's Research Hospital (US), Nationwide Children's Hospital (US), Children's National (US), Harvard University (US), Emory University (US), University of Pittsburgh (US), Baylor College of Medicine (US), George Washington University (US), University of Washington (US), University of Utah (US), University of Michigan (US), University of Minnesota System (US), University of Utah Hospital (US), Cook Children's Medical Center (US), Southwestern Medical Center (US), Cook Children's Health Care System (US), Lurie Children's Hospital (US), Children's Hospital of Pittsburgh (US), Children's Hospital at Montefiore (US), Children's Healthcare of Atlanta (US), University of Colorado Anschutz Medical Campus (US), The Ohio State University (US), University of Nebraska Medical Center (US), University of Cincinnati (US), The University of Texas Southwestern Medical Center (US), University of Cincinnati Medical Center (US), University of Colorado Denver (US)
Good health and well-being
Cytomegalovirus and herpesvirus research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon